A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection

Liver Transplantation and Surgery

Volumn 4, Issue 4, 1998, Pages 276-279

  Fleckenstein, J F ^a   Paredes, M ^a   Thuluvath, P J ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; URSODEOXYCHOLIC ACID;

ADJUVANT THERAPY; ADULT; ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; LIVER TRANSPLANTATION; MALE; MEMBRANE STABILIZATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TARGET CELL;

EID: 0031903083     PISSN: 10743022     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500040412     Document Type: Article

References (12)

1. 1 Klintmalm GBG, Nery JR, Husberg BS, Tillery GW. Rejection in liver transplantation. Hepatology 1989 ; 10: 978–985. MEDLINE
2. 2 Vierling J. Immunologic mechanisms of hepatic allograft rejection. Semin Liver Dis 1992 ; 12: 16–27. MEDLINE
3. 3 Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, Poupon R. Cholestasis induces major histocompatibility complex class 1 expression in hepatocytes. Gastroenterology 1992 ; 102: 1371–1377. MEDLINE
4. 4 Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect ursodeoxycholic acid. Hepatology 1990 ; 11: 12–15. MEDLINE
5. 5 Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992 ; 16: 358–364. MEDLINE
6. 6 Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993 ; 104: 1865–1869. MEDLINE
7. 7 Friman S, Persson H, Schersten T, Svanvik J, Karlberg I. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transplant Proc 1992 ; 24: 389–390. MEDLINE
8. 8 Pageaux GP, Blanc P, Perrigault PF, Navarro F, Fabre M, Souche B, et al. Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol 1995 ; 23: 119–122. MEDLINE
9. 9 Barnes D, Talenti D, Goormastic M, Farquhar L, Cammell M, Henderson M, et al. Ursodeoxycholic acid reduces hepatic allograft rejection after orthotopic liver transplantation—a prospective, randomized, placebocontrolled, double‐blind trial [abstract]. Hepatology 1995 ; 22: 149A.
10. 10 Snover DC, Freese DF, Sharp HL, Bloomer JR, Najarian JS, Ascher NL. Liver allograft rejection: An analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol 1987 ; 11: 1–10. MEDLINE
11. 12 Demetris AJ, Qian S, Sun H, Fung JJ. Liver allograft rejection: An overview of morphologic findings. Am J Surg Pathol 1990 ; 14 (suppl 1): 49–63.
12. 13 Al‐Quaiz M, O'Grady J, Tredger J, Williams R. Variable effect of ursodeoxycholic acid on cyclosporine absorption after orthotopic liver transplantation. Transplant Int 1990 ; 7: 190–194.